Aura Biosciences Q1 net loss $27.5M; appoints Tony Gibney as CFO; Phase 3 CoMpass enrollment may complete by end 2025

Aura Biosciences, Inc.

2025-Q1 EPS reported -$0.55

Net loss $27.5M for Q1 2025 vs $19.7M in Q1 2024; R&D expenses rose to $23.3M from $17.1M.
Cash and marketable securities $128.0M as of March 31, 2025; runway into second half of 2026.
Appointed Tony Gibney as Chief Financial and Business Officer effective May 13, 2025; he brings 30+ years biotech and investment banking experience.
Phase 3 CoMpass trial in early-stage choroidal melanoma actively enrolling; enrollment may complete as early as end 2025.
First patient enrolled in multi-dose Phase 1b/2 trial of bel-sar in NMIBC; initial data at 3 months expected by year-end 2025.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Anthony Gibney

Chief Financial and Business Officer

AURA · Aura Biosciences, Inc.

Effective: 2025-05-13
Filed: May 15, 2025, 7:59 PM ET

Appointment of Chief Financial and Business Officer Effective as of May 13, 2025 (the “Effective Date”), the Board of Directors of the Company appointed Anthony Gibney as the Company’s Chief Financial and Business Officer.

Role change

Amy Elazzouzi

Senior Vice President, Finance

AURA · Aura Biosciences, Inc.

Effective: 2025-05-13
Successor: Anthony Gibney
Filed: May 15, 2025, 7:59 PM ET

Beginning on the Effective Date, Amy Elazzouzi, the Company’s Senior Vice President, Finance, will cease serving as the Company’s principal financial officer and continue as the Company’s principal accounting officer and Mr. Gibney will serve as the Company’s principal financial officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anthony Gibney was appointed as Chief Financial and Business Officer at Aura Biosciences, Inc..

Action: appointed
Role: Chief Financial and Business Officer

Exact text from the filing

Appointment of Chief Financial and Business Officer Effective as of May 13, 2025 (the “Effective Date”), the Board of Directors of the Company appointed Anthony Gibney as the Company’s Chief Financial and Business Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Amy Elazzouzi changed role as Senior Vice President, Finance at Aura Biosciences, Inc..

Action: ceased serving as principal financial officer
Role: Senior Vice President, Finance

Exact text from the filing

Beginning on the Effective Date, Amy Elazzouzi, the Company’s Senior Vice President, Finance, will cease serving as the Company’s principal financial officer and continue as the Company’s principal accounting officer and Mr. Gibney will serve as the Company’s principal financial officer.

View on SEC.gov

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-071839

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.